^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Ceritinib is a novel triple negative breast cancer therapeutic agent

Published date:
06/29/2022
Excerpt:
The combination of ceritinib and enzalutamide showed a robust inhibitory effect on cell growth of AR+ TNBC cells in vitro and in vivo….The combination of paclitaxel and ceritinib showed drastic inhibition of tumor growth compared to a single drug alone....All agents used in our study are FDA-approved, and thus the proposed combination therapy will likely be useful in the clinic.
Secondary therapy:
paclitaxel
DOI:
10.1186/s12943-022-01601-0